Henagliflozin-Metformin combo can be an alternative choice for diabetics nonresponsive to Metformin

      Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a novel class of antidiabetic drugs with proven efficacy to control glucose levels and to achieve glycemic targets. Henagliflozin is a sodium-glucose transporter 2 inhibitor developed by the Jiangsu HengRui Medicine. The pharmacokinetic and pharmacodynamic profiles of Henagliflozin evaluated in the trials conducted in Chinese patients supports a once-daily dosing regimen in T2D patients. Recent study on Henagliflozin conducted by Dr. Jian Weng and his team which got published in the journal Diabetes Metabolism and Obesity revealed that it can be coadministered with Metformin in patients with T2D and in cases where Metformin shows inadequacy in its performance.

      The outcomes of the study showed that both 5mg and 10 mg of Henagliflozin lowered fasting plasma glucose, 2‐hour postprandial plasma glucose, body weight, blood pressure and increased the proportions of patients achieving HbA1c <7.0% when compared with the Placebo group.

      The researchers concluded that the drug molecule 5 or 10 mg as add‐on therapy to metformin gives insights into a novel therapeutic choice for treatment of T2DM patients who have inadequate glycemic control with metformin alone, and were generally well tolerated.

Read More

Imeglimin monotherapy significantly improves HbA1c in Type 2 diabetes

      Imeglimin is a novel oral antidiabetic investigational drug molecule to treat type 2 diabetes. The mode of action of Imeglimin involves the targeting of mitochondrial bioenergetics and improving mitochondrial function. This antidiabetic agent has been shown to amplify glucose-stimulated insulin secretion by improving β-cell glucose responsiveness and insulin sensitivity in individuals with type 2 diabetes.

      The Phase 1 and Phase 2 clinical trials in Caucasian patients with type 2 diabetes demonstrated that Imeglimin is efficacious as monotherapy and has an adequate safety and tolerability profile. Also, Imeglimin is well-tolerated as add-on therapy to metformin and sitagliptin, emphasizing its potential for add-on therapy with common oral antidiabetic agents.

      A recently published study in Diabetes Care which investigated the safety and efficacy of Imeglimin, revealed that the drug contributes to significant improvements in glycemic control. The study was a double-blind, randomized, parallel-group, placebo-controlled phase 3 trial conducted in 30 sites in Japan. The primary endpoint was the change in mean HbA1c from baseline to week 24, and the secondary endpoint was the percentage of responders at week 24. At week 24, HbA1c had significantly decreased by 0.72%) with Imeglimin versus a nonsignificant increase of 0.15% with placebo. FPG and fasting proinsulin/C-peptide ratio were significantly decreased compared with placebo after 24 weeks of treatment.

      According to the investigators, Imeglimin can be considered as a promising oral agent for the treatment of patients with type 2 diabetes, in particular in the elderly population.

Read More:

mySugr app integrates with Novo Nordisk’s smart insulin pens

      The most popularly used mySugr app from Roche is integrating its Logbook with Novo Nordisk's smart pens, NovoPen 6 and NovoPen Echo Plus for increasing the efficiency of data collection. As per the announcement from the manufacturers' patients will be able to connect the mySugr Logbook to their smart-pen device and can generate more data set and reports with more insights on their glucose level. The integration will also aid healthcare professionals in better analysis of data for accurate decision making. The combination of NovoPen, NovoPen Echo Plus and mySugr will be yet another breakthrough leap in offering an open ecosystem that aids to improve the quality of patient-physician interaction and supports a more holistic and personalized therapy outcome.

Read More: